NCT02913430View on ClinicalTrials.gov

Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

April 24, 2018

Primary Completion Date

April 12, 2022

Study Completion Date

April 30, 2024

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Fulvestrant

500mg IM Q28 days

DRUG

Tamoxifen

20mg PO Qdaily

DRUG

Palbociclib

Tamoxifen or Fulvestrant plus palbociclib125mg/day PO on a 21 days on/7 days off schedule

Trial Locations (1)

15213

Magee-Womens Hospital UPMC, Pittsburgh

All Listed Sponsors
lead

Shannon Puhalla

OTHER

NCT02913430 - Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib | Biotech Hunter | Biotech Hunter